These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 17885815

  • 1. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
    Shiu LY, Liang CH, Huang YS, Sheu HM, Kuo KW.
    Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
    [Abstract] [Full Text] [Related]

  • 2. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
    Shiu LY, Liang CH, Chang LC, Sheu HM, Tsai EM, Kuo KW.
    Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
    [Abstract] [Full Text] [Related]

  • 3. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin.
    Shiu LY, Chang LC, Liang CH, Huang YS, Sheu HM, Kuo KW.
    Food Chem Toxicol; 2007 Nov; 45(11):2155-64. PubMed ID: 17619073
    [Abstract] [Full Text] [Related]

  • 4. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells.
    Liang CH, Shiu LY, Chang LC, Sheu HM, Kuo KW.
    Mol Nutr Food Res; 2007 Aug; 51(8):999-1005. PubMed ID: 17639997
    [Abstract] [Full Text] [Related]

  • 5. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
    Liang CH, Shiu LY, Chang LC, Sheu HM, Tsai EM, Kuo KW.
    Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
    [Abstract] [Full Text] [Related]

  • 6. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.
    J Surg Res; 2006 May 15; 132(2):208-13. PubMed ID: 16580691
    [Abstract] [Full Text] [Related]

  • 7. HER2/neu antisense targeting of human breast carcinoma.
    Roh H, Pippin JA, Green DW, Boswell CB, Hirose CT, Mokadam N, Drebin JA.
    Oncogene; 2000 Dec 11; 19(53):6138-43. PubMed ID: 11156527
    [Abstract] [Full Text] [Related]

  • 8. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur AB.
    Int J Pharm; 2007 Aug 16; 341(1-2):221-9. PubMed ID: 17499461
    [Abstract] [Full Text] [Related]

  • 9. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
    Pommier SJ, Quan GG, Christante D, Muller P, Newell AE, Olson SB, Diggs B, Muldoon L, Neuwelt E, Pommier RF.
    Ann Surg Oncol; 2010 Feb 16; 17(2):613-23. PubMed ID: 19838757
    [Abstract] [Full Text] [Related]

  • 10. [Geldanamycin inhibits proliferation and motility of human HER2/neu-overexpressing breast cancer cell line SKBr3].
    Wang K, Ma QY, Ren Y, He JJ, Chen WK.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct 16; 27(10):1480-4. PubMed ID: 17959518
    [Abstract] [Full Text] [Related]

  • 11. Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy.
    Chuang TC, Liu JY, Lin CT, Tang YT, Yeh MH, Chang SC, Li JW, Kao MC.
    FEBS Lett; 2007 Sep 18; 581(23):4443-9. PubMed ID: 17719580
    [Abstract] [Full Text] [Related]

  • 12. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ.
    Oncogene; 1997 Jul 31; 15(5):537-47. PubMed ID: 9247307
    [Abstract] [Full Text] [Related]

  • 13. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
    Tuna M, Chavez-Reyes A, Tari AM.
    Oncogene; 2005 Feb 24; 24(9):1648-52. PubMed ID: 15674342
    [Abstract] [Full Text] [Related]

  • 14. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M, Imura J, Kozaki T, Fujimori T, Asakawa S, Shimizu N, Kawaguchi R.
    Oncol Rep; 2005 Apr 24; 13(4):633-41. PubMed ID: 15756435
    [Abstract] [Full Text] [Related]

  • 15. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
    Roh H, Pippin J, Boswell C, Drebin JA.
    J Surg Res; 1998 Jun 24; 77(1):85-90. PubMed ID: 9698539
    [Abstract] [Full Text] [Related]

  • 16. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
    Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, Bologna M.
    Urology; 2009 Aug 24; 74(2):452-7. PubMed ID: 19285710
    [Abstract] [Full Text] [Related]

  • 17. Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression.
    Pierpaoli E, Viola V, Pilolli F, Piroddi M, Galli F, Provinciali M.
    Life Sci; 2010 Apr 24; 86(17-18):668-75. PubMed ID: 20188744
    [Abstract] [Full Text] [Related]

  • 18. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.
    Mitchell MS, Press MF.
    Semin Oncol; 1999 Aug 24; 26(4 Suppl 12):108-16. PubMed ID: 10482202
    [Abstract] [Full Text] [Related]

  • 19. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
    Zhou Z, Jia SF, Hung MC, Kleinerman ES.
    Cancer Res; 2001 Apr 15; 61(8):3394-8. PubMed ID: 11309298
    [Abstract] [Full Text] [Related]

  • 20. Expression of HER2/neu in primary and metastatic breast cancer.
    Tuziak T, Olszewski WP, Olszewski W, Pieńkowski T.
    Pol J Pathol; 2001 Apr 15; 52(1-2):21-6. PubMed ID: 11505677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.